Abstract Search

14.9. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

SA Harrison , MR Bashir , CD Guy , R Zhou , CA Moylan , JP Frias , N Alkhouri , MB Bansal , S Baum , BA Neuschwander-Tetri , R Taub , SE Moussa

To read the full abstract: Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6.Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist. This 36-week long randomised, placebo-controlled trial in 348 US adults with biopsy confirmed non-alcoholic steatohepatitis (fibrosis stages 13) shows that Resmetirom...

0 shares

ey0021.15-2 | New Treatments | ESPEYB21

15.2. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

SA Harrison , P Bedossa , CD Guy , JM Schattenberg , R Loomba , R Taub , D Labriola , SE Moussa , GW Neff , ME Rinella , QM Anstee , MF Abdelmalek , Z Younossi , SJ Baum , S Francque , MR Charlton , PN Newsome , N Lanthier , I Schiefke , A Mangia , JM Pericas , R Patil , AJ Sanyal , M Noureddin , MB Bansal , N Alkhouri , L Castera , M Rudraraju , V Ratziu , the MAESTRO-NASH Investigators.

In Brief This phase 3 trial including 966 adults with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis were randomly assigned (1:1:1 ratio) to once-daily resmetirom 80 mg or 100 mg or placebo. Resmetirom, both 80 and 100 mg daily, were superior to placebo with respect to NASH resolution and improvement in liver fibrosis.NASH resolution occurred more frequently in patients on 80-mg (25.9%) and 100-mg resmetirom (29.9%) than on placebo (...

0 shares

ESPE Yearbook of Paediatric Endocrinology

14.9. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

15.2. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

BiosciAbstracts